Adding liposomal transcrocetin to radiation and chemotherapy for newly diagnosed glioblastoma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether adding an experimental drug called liposomal transcrocetin (L-TC) to the standard treatment of radiation and temozolomide chemotherapy helps people with newly diagnosed glioblastoma. It aims to see if the combination improves outcomes compared to standard care alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with glioblastoma (a type of brain cancer) and have not had any previous treatment for it except possibly surgery.
- Your age matters: if you are 18–70, you must not have had surgery (non-operable). If you are over 70, you may have had surgery or not.
- You need to be in fairly good general health (Karnofsky score of at least 50% if 18–70, or at least 70% if over 70).
- Your blood and kidney/liver function must be within certain limits within 2 weeks before starting the trial.
- You must not have had radiation therapy to the brain before.
- You must be willing to use effective contraception if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests whether adding a special type of radiofrequency electromagnetic field treatment to standard chemotherapy and radiation therapy helps people with newly diagnosed glioblastoma. It is for patients who are planning to receive standard treatment and have had surgery to remove the tumor.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This trial tests whether adding the drug ruxolitinib to standard radiation and chemotherapy (temozolomide) helps people with a newly diagnosed brain tumor called glioblastoma. It aims to see if the combination keeps the tumor from growing longer than the standard treatment alone.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.